# Made available by Hasselt University Library in https://documentserver.uhasselt.be

Different Safety Pattern of Ticagrelor Monotherapy Following Percutaneous Coronary Interventions Related to Pulse Pressure Levels: A Subanalysis of the GLOBAL LEADERS Randomized Multicenter Trial Peer-reviewed author version

de Faria, Ana Paula; Modolo, Rodrigo; Chichareon, Ply; Chang, Chun-Chin; Kogame, Norihiro; Tomaniak, Mariusz; Wykrzykowska, Joanna; de Winter, Robert; Hamm, Christian; Juni, Peter; VRANCKX, Pascal; Valgimigli, Marco; Windecker, Stephan; Onuma, Yoshinobu & Serruys, Patrick (2019) Different Safety Pattern of Ticagrelor Monotherapy Following Percutaneous Coronary Interventions Related to Pulse Pressure Levels: A Subanalysis of the GLOBAL LEADERS Randomized Multicenter Trial. In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 74(13), p. B409-B409.

Handle: http://hdl.handle.net/1942/29872

1	Different safety pattern of ticagrelor monotherapy following percutaneous coronary
2	interventions related to pulse pressure levels: A sub-analysis of the GLOBAL
3	LEADERS randomized multicenter trial
4	Ana Paula de Faria*, PhD <sup>a</sup> ; Rodrigo Modolo*, MD <sup>b,c</sup> ; Ply Chichareon*, MD <sup>b,d</sup> ; Chun-Chin
5	Chang, MD <sup>e</sup> ; Norihiro Kogame, MD <sup>b</sup> ; Mariusz Tomaniak MD <sup>e,f</sup> ; Kuniaki Takahashi, MD <sup>b</sup> ;
6	Tessa Rademaker-Havinga, MSc <sup>g</sup> ; Joanna Wykrzykowska, MD, PhD <sup>b</sup> ; Rob J. de Winter,
7	MD, PhD <sup>b</sup> ; Rui C. Ferreira, MD <sup>h</sup> ; Amanda Sousa, MD, PhD <sup>i</sup> ; Pedro A. Lemos, MD, PhD <sup>j</sup> ;
8	Scot Garg, MBChB, PhD <sup>k</sup> Christian Hamm MD <sup>1</sup> , Philippe Gabriel Steg MD, PhD <sup>m,n</sup> , Peter
9	Juni MD, PhD <sup>o</sup> , Pascal Vranckx, MD, PhD <sup>p</sup> , Marco Valgimigli, MD, PhD <sup>q</sup> , Stephan
10	Windecker, MD, PhD <sup>q</sup> , Yoshinobu Onuma, MD, PhD <sup>e,g</sup> , Patrick W. Serruys MD, PhD <sup>r</sup>
11	
12	*These authors contributed equally to this manuscript
13	Affiliations
14	<sup>a</sup> School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil. <sup>b</sup> Department of Cardiology,
15	Amsterdam University Medical Center, Amsterdam, the Netherlands. Department of Internal Medicine,
16 17	Cardiology Division. University of Campinas (UNICAMP). Campinas, Brazil. <sup>d</sup> Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand. <sup>e</sup> Erasmus Medical
18	Center, Erasmus University, Rotterdam, the Netherlands. <sup>f</sup> First Department of Cardiology, Medical University of
19	Warsaw, Warsaw, Poland. <sup>g</sup> Cardialysis Clinical Trials Management and Core Laboratories, Westblaak 98,
20	Rotterdam, the Netherlands. <sup>h</sup> Serviço de Cardiologia, Hospital de Santa Marta, Centro Hospitalar Universitário
21 22	Lisboa Central, Lisbon, Portugal. <sup>1</sup> Department of Interventional Cardiology, Instituto Dante Pazzanese de
23	Cardiologia, Sao Paulo, Brazil. <sup>!</sup> Instituto do Coração - HCFMUSP, Universidade de São Paulo, São Paulo, Brazil. <sup>k</sup> East Lancashire Hospitals NHS Trust, Blackburn, Lancashire, United Kingdom. <sup>!</sup> Kerckhoff Heart Center,
24	Campus University of Giessen, Bad Nauheim, Germany. <sup>m</sup> FACT, French Alliance for Cardiovascular Trials; Hôpital
25	Bichat, AP-HP; Université Paris-Diderot; and INSERM U-1148, all in Paris, France." Royal Brompton Hospital,
26	Imperial College, London, United Kingdom. <sup>o</sup> Applied Health Research Centre, Li Ka Shing Knowledge Institute, St
27 28	Michael's Hospital, University of Toronto, Toronto, Canada. <sup>p</sup> Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Hasselt, Belgium. <sup>q</sup> Department of Cardiology, Bern University
29	Hospital, Bern, Switzerland 'NHLI, Imperial College London, London, United Kingdom.
30	
31	Address for correspondence:
32	Professor Patrick W. Serruys, MD, PhD.
33	Professor of Medicine (em) - Erasmus University Medical Center, Rotterdam, The
34	Netherlands.
35	Professor of Cardiology (hon) - Imperial College London, London, The United Kingdom
36	P.O. Box 2125, 3000 CC Rotterdam, the Netherlands
37	Email: patrick.w.j.c.serruys@gmail.com
38	Number of figures: 2, Number of tables: 3
38 39	Word count: 5,273
40	Sources of funding: GLOBAL LEADERS was sponsored by the European Clinical
τu	Sources of running. OLODAL LEADERS was sponsored by the European Chillean

- 41 Research Institute, which received funding from Biosensors International, AstraZeneca, and
- 42 the Medicines Company.

43 Abstract

44 **Aims:** The relationship between pulse pressure (PP) data and clinical outcomes after

45 contemporary percutaneous coronary intervention (PCI) is poorly defined. Therefore, we

46 evaluated the impact of PP and different antiplatelet regimes on clinical and safety outcomes

47 in an all-comers population.

48 Methods: In this sub-analysis of the GLOBAL LEADERS trial (n=15,936) we compared the

49 experimental therapy of 23-month ticagrelor following one-month dual anti-platelet therapy

50 (DAPT), versus standard DAPT for 12 months followed by aspirin monotherapy, in all-

51 comers subjects who underwent PCI and were divided into two groups according to the

52 median PP of 60 mmHg. The adjudicated primary endpoint (composite of all-cause death or

new Q-wave myocardial infarction) and the composite endpoints (1) patient oriented

54 composite endpoints (POCE), (2) secondary safety bleeding endpoint BARC types 3 or 5,

and (3) net adverse clinical events (NACE) were evaluated.

56 **Results:** At 2 years, subjects in the high PP group (n=7,971) had numerically higher rates of

57 the primary endpoint (4.3% vs. 3.9%, p=0.058), similar BARC 3 or 5 bleeding (2.5% vs.

58 1.7%, p=0.355) and higher rates of NACE (16.4% versus 13.7%, p=0.037), and POCE

59 (14.9% vs. 12.7%, p=0.051), compared with the low PP group (n=7,965), respectively. There

60 was no treatment effect of ticagrelor monotherapy compared with standard DAPT among

61 patients with high PP levels for the studied outcomes. Among patients with arterial

62 compliance (PP<60mmHg), the primary endpoint (3.4% vs. 4.4%, adjusted HR 0.77 [0.61-

63 0.96], p=0.022, p<sub>interaction</sub>=0.103) POCE (11.8% vs. 13.5%, aHR 0.86 [0.76-0.98], p=0.019,

64 pinteraction=0.132), NACE (12.8% vs. 14.7%, aHR 0.85 [0.76-0.96], p=0.009, pinteraction=0.081)

65 and BARC 3 or 5 (1.4 vs. 2.1%, aHR 0.69 [0.49-0.97], p=0.036; p<sub>interaction</sub> =0.008) were lower

66 with the use of ticagrelor monotherapy compared with the standard DAPT.

67	Conclusions: After contemporary PCI subjects with high PP levels (arterial stiffness)
68	experienced high rates of the combination of clinically relevant ischemic events and safety-
69	related bleeding events at 2-years follow-up. In those with low PP levels, ticagrelor
70	monotherapy led to a lower risk of bleeding events compared to standard DAPT.
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	

#### 92 Introduction

93 Pulse pressure (PP) is the pulsatile component of blood pressure (BP) and can predict cardiovascular outcomes (1). A rise in PP, which is mainly observed in middle-aged and 94 95 elderly patients due to an increase in systolic BP (SBP) and decrease in diastolic BP (DBP), 96 is considered a marker of underlying vascular disease, and reflects a reduction in arterial 97 compliance (2). Specifically, in patients with coronary artery disease (CAD), aortic PP significantly predicted major adverse cardiovascular events and all-cause mortality (3). 98 99 Brachial PP levels were also independently associated with all-cause mortality in CAD patients after percutaneous coronary intervention (PCI) at 5-year follow-up (4). Recently, a 100 101 retrospective study has demonstrated that the combination of high SBP and low DBP - a 102 wide PP - prior to PCI is associated with myocardial infarction and stroke at 1-year post-103 procedure (5). However, the relationship between PP and clinical outcomes have been poorly 104 explored in clinical trials of large populations of patients with CAD who have undergone 105 contemporary PCI.

106 Recently, the GLOBAL LEADERS trial has shown that 23-month ticagrelor 107 monotherapy, following one-month dual anti-platelet therapy (DAPT), was not superior to 108 standard DAPT in preventing the primary endpoint – all-cause mortality or new Q-wave 109 myocardial infarction (MI) – among all-comers patients 2 years after PCI (6). Rates of the 110 secondary composite endpoints (i) major bleeding (type 3 or 5 according to Bleeding Academic Research Consortium -BARC) (6), (ii) patient-oriented composite endpoints 111 112 (POCE), and (iii) net adverse clinical events (NACE), which combines POCE and bleeding 113 events (7), were also similar between the two antiplatelet strategies. Nevertheless, ticagrelor 114 monotherapy was shown to be effective and safe (6).

In this sub-analysis of the GLOBAL LEADERS trial, which enrolled a large 'reallife' population we sought to evaluate: (i) the impact of PP on clinical outcomes following

contemporary PCI and (ii) the impact of different antiplatelet strategies on the 2-year clinical
and safety outcomes in all-comers patients who underwent PCI stratified by low and high PP.

120 Methods

121 The trial

122 The present study is a sub-analysis of the GLOBAL LEADERS trial (ClinicalTrials.gov, number NCT01813435) described in detail elsewhere (6,8). In brief, the 123 124 trial was a randomized, open-label, multicenter, superiority study designed to compare two antiplatelet therapy strategies in all-comers patients after PCI with a biolimus A9-eluting 125 126 stent. The experimental therapy comprised aspirin (75–100 mg) daily plus ticagrelor (90 mg) 127 twice daily for 1 month, followed by 23 months of ticagrelor monotherapy, while reference therapy was standard DAPT with aspirin (75–100 mg) daily plus either clopidogrel (75 mg) 128 129 daily (for patients with stable coronary artery disease) or ticagrelor (90 mg) twice daily (for 130 patients with acute coronary syndrome-ACS) for 12 months, followed by aspirin 131 monotherapy for  $12 \mod (6,8)$ . 132 The trial was approved by the institutional review board at each participating institution. The study was performed in accordance with the ethical principles for medical 133 research involving human subjects of the World Medical Association (Declaration of 134 135 Helsinki), the International Conference of Harmonization, and Good Clinical Practice. All 136 participants provided written informed consent at enrolment. An independent data and safety 137 monitoring committee oversaw the safety of all patients.

138 Study population

The main study enrolled 15,991 patients between July 2013 to November 2015 in an
"all-comers" design: no restriction regarding clinical presentation, complexity of the lesions
or number of stents used. Since (i) 23 patients withdrew consent and requested data deletion

142 from the database, and (ii) 32 subjects had systolic and diastolic BP levels equal to zero

143 (treated as mistakes in completion of the eCRF, and then excluded), a total of 15,936 subjects

144 remained for the current analysis (99.65% of all randomized patients).

145 Pulse Pressure

PP was calculated by subtracting the DBP from the SBP recorded at the time of
randomization by a single seated BP. Patients were then divided into two groups using the
median PP of 60 mmHg as a cut-off into the low (PP <60mmHg) and high (PP≥60 mmHg)</li>
group.

150 Study endpoints

151 In this sub-analysis of the GLOBAL LEADERS trial we evaluated the impact of PP 152 and different antiplatelet strategies on the primary endpoint – a composite of investigator-153 reported all-cause mortality or non-fatal, new Q-wave MI identified by an independent ECG core laboratory (6) – at 2 years in all-comers subjects who underwent PCI stratified by low or 154 155 high baseline PP. Secondarily, we assessed the interaction of these anti-platelet therapies on 156 (i) the key secondary safety endpoint – site-reported bleeding assessed according to the 157 BARC criteria (grade 3 or 5) (9), (ii) the POCE and (iii) NACE at 2 years in PP groups. 158 POCE was defined according to the recent Academic Research Consortium (ARC)-2 159 consensus as all-cause mortality, any stroke (ischemic and hemorrhagic), any MI including 160 periprocedural or spontaneous with ST-elevation MI (STEMI) or non-ST-segment elevation 161 myocardial infarction (NSTEMI), and any revascularization (re-PCI or coronary artery 162 bypass graft surgery (CABG) in target or non-target vessels) (10) NACE was defined as the 163 combination of clinically relevant ischemic events and safety-related bleeding events, POCE 164 plus BARC type 3 or 5. The composite endpoints were analyzed according to time-to-first 165 event analysis.

166 Statistical analyses

167 Continuous variables are expressed as mean  $\pm$  standard deviation and were compared 168 using independent t test. Categorical variables are presented as absolute number and 169 percentage and were compared using Chi square test. Kaplan-Meier method was used to 170 estimate the cumulative rates of events and log-rank test was performed to examine the 171 differences between groups. The outcomes according to PP groups were assessed in the 172 univariate and multivariate Cox proportional hazards model. The covariates in the multivariate model were included based on clinical relevance as well as association with PP 173 174 in previous studies, such as age, diabetes, sex, hypertension, peripheral vascular disease, renal failure, history of MI, history of coronary artery bypass grafting and presentation of 175 176 ACS. Hazard ratio (HR) and 95% confidence intervals (CI) were calculated, and interaction 177 test was performed to evaluate the differences in the treatment effect of antiplatelet strategies in PP groups. Association between the continuous PP levels and clinical (POCE) and safety 178 179 bleeding (BARC 3 or 5) outcomes were assessed using spline function in the Cox regression 180 analysis. All the analyses were performed according to the intention-to-treat principle of all 181 randomized patients as time-to-first-event. A two-sided alpha of 5% was considered as 182 statistical significance. The analyses were performed in R version 3.4.2.

183

184 **Results** 

#### 185 Baseline clinical characteristics

Out of 15,936 subjects who remained in this sub-analysis of the GLOBAL LEADERS trial, 7,965 had a low PP (PP<60 mmHg), and 7,971 had a high level (PP $\ge$  60 mmHg). As expected, those in the high PP group were older and more likely to be women, diabetic (and insulin users), hypertensive and hypercholesterolemic compared with their counterparts. In addition, this group with a PP $\ge$ 60mmHg had a higher proportion of patients with peripheral vascular disease, renal failure, previous coronary artery bypass grafting and stable coronary

192 artery disease compared to patients in the low PP group. On the other hand, compared with

193 those with a PP≥60mmHg, patients with in the low PP group were more commonly smokers,

and more likely to present with a NSTEMI or STEMI (Table 1).

#### 195 Impact of pulse pressure levels on clinical outcomes

196 As shown in table 2 in the univariate model, at 2 years, rates of primary endpoint – 197 the composite of all-cause mortality or non-fatal new Q-wave MI – were similar between the 198 PP groups, whereas POCE, NACE and BARC 3 or 5 occurred more frequently in group with 199 PP≥60mmHg. Multivariate analyses revealed that subjects with high PP levels had 200 significantly higher rates of NACE, although POCE and the primary endpoint were 201 numerically higher without reaching statistical significance, compared with the group with low PP levels. In the multivariate model rates of BARC 3 or 5 bleeding were similar between 202 203 the PP groups (Table 2). Spline representation of the hazard ratios for POCE and BARC 3 or 204 5 are shown in **Figure 1**.

#### 205 Impact of antiplatelet strategies on clinical and safety outcomes

206 No treatment effect of ticagrelor monotherapy compared with standard DAPT was 207 observed among patients with a high PP for the studied outcomes. On the other hand, subjects 208 with a low PP treated with ticagrelor had a lower risk of the clinical and safety outcomes 209 assessed in this sub-analysis – the primary endpoint, POCE, NACE and BARC 3 or 5 – 210 compared with standard DAPT (Table 3). Interaction testing revealed differences in the treatment effect of antiplatelet strategies between PP groups with regards to the secondary 211 212 safety outcome only - BARC 3 or 5 bleeding events - p<sub>interaction</sub> = 0.008 (Table 3). Time to 213 first event curves for the secondary endpoints and interaction with the antiplatelet treatment 214 strategy are shown in **Figure 2**.

215

#### 216 Discussion

217 The main findings of this sub-analysis of the GLOBAL LEADERS trial are (1) at two 218 years follow-up, regardless of confounders, patients with high PP have significantly higher 219 rates of NACE compared to those with low PP; and (2) a significant difference in 2-yearsafety outcomes was observed between the antiplatelet strategies and PP groups: the 220 221 experimental therapy of ticagrelor monotherapy was superior to standard DAPT in lowering 222 the risk of BARC 3 or 5 bleeding in subjects with low PP, whilst no difference was observed 223 among those with high PP. Given the trial design, our study is the first to examine the 224 interaction between PP and antiplatelet scheme on ischemic and safety outcomes in an all-225 comers population after contemporary PCI.

226 Studies have clearly pointed out that cardiovascular risk is related not only to an 227 increase in systolic but also to a decrease in diastolic BP. Since both components of BP tend 228 to diverge after the age of 55 (11), PP has emerged as an important risk factor for predicting 229 cardiovascular events (1,12). PP increases along with age, body mass index, cholesterol, and risk of diabetes, but independent of these risk factors, it has been shown to be a strong 230 231 predictor of death from cardiovascular disease with an increased risk of 10% in individuals 232 46 to 77 years of age, per 10 mmHg increment in PP (13). Rises in PP, which reflect a 233 reduction in arterial compliance, have been identified as a simple marker of underlying 234 vascular disease (2). As PP has been reported to be a good indicator of arterial stiffness, 235 especially in older people, it may be considered an accurate assessment of vascular bed 236 compliance (11, 14).

Adverse outcomes in patients with CAD have been associated with elevated PP. Ascending aortic PP normalized to the mean BP correlated to the extent of coronary atherosclerosis irrespectively of the presence of hypertension (15), as well as being able to predict the risk of major adverse cardiovascular events and all-cause mortality (3) in individuals with angiographically proven CAD. Specifically in CAD patients following PCI,

242 mean BP-normalized PP was a powerful predictor of restenosis 3 months after the procedure 243 [Odds Ratio = 33.5 (95% CI, 2.04 to 550.6) for the highest, compared with the lowest, tertile 244 of PP] (16). Brachial PP levels were also independently associated with total mortality [Relative Risk=1.08 (95%CI, 1.01 to 1.15, per 10 mmHg increment in PP] in coronary 245 246 patients followed for 5 years after revascularization (4). Further, increased noninvasive heart 247 rate-corrected aortic amplification index, which assess arterial stiffness (17,18), predicted the occurrence of the combination of death, MI, and clinical restenosis in CAD patients within 2 248 249 years of their PCI (19). Most recently, a large retrospective analysis associated pre-250 procedural PP (high systolic combined with low diastolic BP) with a higher incidence of MI 251 and stroke at 1 year after PCI (5). Our findings are in part consistent with those previous 252 studies. We found that after adjusting for several confounders, subjects with high baseline PP 253 who underwent PCI were at an increased risk (9% risk increase along the 2 years) of having 254 the combination of clinically relevant ischemic events and safety-related bleeding events, namely NACE. Of the components of NACE, safety-related bleeding (BARC 3 or 5) has 255 256 previously been poorly explored in relation to an association with baseline PP in subjects 257 undergoing PCI. Our study supports the prognostic importance of PP- that reflect increased arterial stiffness - on subsequent cardiovascular outcomes and bleeding events in patients 258 259 after PCI.

The pathophysiology of the effects of increased PP is complex. It causes increased cyclic stretch of vascular structures activating several signaling pathways ultimately leading to atherosclerotic remodeling, proinflammatory cell migration, and increases in oxidative stress (20). A bidirectional link is also present; while on the one hand elevated PP mediates progression of atherosclerosis, on the other hand, plaque formation impairs the elastic properties of the arterial wall, elevating PP, creating a vicious cycle (20-22). Pulsatile BP has been implicated as the main mechanism causing instability and rupture of atherosclerotic

267 plaque, and consequently acute coronary syndrome and other vascular complications (23,24). 268 In fact, studies have suggested that cardiac events are more related to the pulsatile stress of large-artery stiffness during systole – as reflected by a rise in PP – than the steady-state stress 269 270 of small-vessel resistance during diastole (as reflected in rises in both systolic and diastolic 271 BP) (25). Rises in aortic stiffness have also supported the link between cardiac performance 272 and myocardial perfusion. It has been shown that among patients undergoing PCI, compared 273 to those with compliant aortas, those with stiffer aortas had a lower hyperemic coronary 274 blood flow response to adenosine, and also a smaller improvement in hyperemic coronary 275 blood flow after a successful PCI (26). These data demonstrate that, because the arterial wall 276 continuously interacts with hemodynamic forces, the PP, reflecting increased arterial 277 stiffness, might in part, be the mechanical component underlying adverse cardiovascular and 278 bleeding events.

279 The most interesting finding and the novelty of this sub-analysis of GLOBAL 280 LEADERS trial was that prolonged ticagrelor monotherapy was beneficial in reducing the 281 risk of bleeding events compared to conventional DAPT followed by aspirin alone in subjects 282 who had low PP, although no different effect was observed between the therapies in those with high PP. Since the relevant PLATO (The Study of Platelet Inhibition and Patient 283 284 Outcomes) trial (27) revealed the superiority of ticagrelor over clopidogrel with regard to the 285 primary efficacy endpoint without an increase in the rate of major bleeding in patients with 286 ACS, protective effects of ticagrelor have been extensively explored in the literature (28,29). 287 These pleiotropic effects – mainly reported due to increasing adenosine levels (30-32) – have 288 been associated with (i) improvements in endothelial function when compared with 289 clopidogrel (28,29), and (ii) increases in circulating endothelial progenitor cell levels (EPC) 290 and decreases in proinflammatory cytokines compared with prasugrel (33). In fact, studies 291 have suggested that increasing circulating EPC in ACS subjects is critical to improve

292 vascular healing and regenerate endothelial homeostasis (34). In addition, by reducing acute 293 systemic inflammation, ticagrelor may modulate arterial stiffness (35). Beyond its potency in 294 inhibiting platelet aggregation, ticagrelor seems to have additional vascular protective 295 properties. In light of these data, our study demonstrated that subjects who underwent PCI 296 and had a low PP –reflecting a healthier profile of arterial compliance – were the target group 297 who, possibly due to ticagrelor-related pleiotropic effects, have a reduced risk of bleeding 298 from ticagrelor compared to DAPT. On the other hand, no effect of ticagrelor on 299 cardiovascular and bleeding events was noticeable in the group with high PP, which probably 300 reflects their more advanced arterial stiffness. Although ticagrelor was not found to be more 301 effective than DAPT in reducing cardiovascular outcomes (p values for interaction were not 302 significant), its safety profile after PCI with low PP is of particular importance.

303 Accordingly, anti-platelet therapy in individuals with high BP, who presented either 304 with cardiovascular or cerebrovascular disease, has been associated with an increased risk for 305 hemorrhagic stroke (36-38). Nevertheless, recent guidelines for the management of arterial 306 hypertension (39), based mainly on a Cochrane systematic review (40), state that for 307 secondary prevention the benefit of aspirin in patients with elevated BP is many times greater 308 than the harm (an absolute reduction in vascular events of 4.1% compared with placebo). 309 However, antiplatelet agents such as ticlopidine, clopidogrel, and newer prasugrel and 310 ticagrelor have not been sufficiently evaluated in these hypertensive patients (39). Although 311 our findings showed similar rates of clinical and safety outcomes in taking either ticagrelor or 312 DAPT at 2 year-follow up in subjects with high PP, future research is necessary to delineate 313 this relationship more precisely.

314

315 Limitations

316 The main limitation is our sub-analysis is exploratory and was not a prespecified 317 analysis of the GLOBAL LEADERS trial, therefore, the results should be considered as 318 hypothesis-generating. The trial did not have a clinical adjudication committee for serious 319 adverse events due to limited financial resources. An exception of primary endpoint - all-320 cause death and new Q wave MI – assessed by an independent ECG core lab, the endpoints 321 were site-reported. However, the trial was monitored for consistency and reporting of events 322 and on-site monitoring visits were regularly performed. As we based our analyses on single 323 office PP, it would be more accurate and precise by using the mean of multiple BP readings 324 or ambulatory monitoring. Central PP is shown to predict cardiovascular events (41) and 325 associate with coronary atherosclerosis (42) more strongly than peripheral measurements, but 326 aortic measurements are not assessed in the trial. On the other hand, the difference between 327 central and peripheral PP observed in younger individuals is not as evident as in the elderly 328 population (43) – which favours our findings on brachial PP evaluation since the population 329 included in the GLOBAL LEADERS trial had a mean of 64.5 years of age (6). Nonetheless, a 330 meta-analysis has supported that central PP does not offer a significant increase in predictive 331 ability for clinical events over peripheral PP (44).

332

#### 333 Conclusions

Subjects with high PP experienced higher rates of the combination of clinically
relevant ischemic events and safety-related bleeding events (NACE) at two years after PCI
compared to those at low level. In addition, ticagrelor monotherapy was favorable to standard
DAPT strategy in providing a lower risk of bleeding events (BARC 3 or 5) in patients with
low PP.

339

340 **Perspectives** 

341	Following the advantages ticagrelor has demonstrated over traditional antiplatelet
342	therapy (27,45,46), our findings suggest that patients undergoing PCI with a low PP – thus
343	reflecting more compliant arteries – may benefit from ticagrelor monotherapy compared to
344	DAPT due to the lower risk of bleeding events. Although ticagrelor was not found to be more
345	effective than DAPT in reducing clinical outcomes, its safety pattern in patients with low PP
346	is of great importance in clinical practice. Since the population we studied reflects modern
347	clinical practice, PP – easily assessed in routine practice – can help stratify and guide, after
348	PCI, patients who can benefit from different antiplatelet therapies. The results should be
349	interpreted as hypothesis-generating, therefore prospective confirmation of our results is
350	needed.

## 351 References

- Benetos A, Zureik M, Morcet J et al. A decrease in diastolic blood pressure combined
   with an increase in systolic blood pressure is associated with a higher cardiovascular
   mortality in men. J Am Coll Cardiol 2000;35:673-80.
- 355 2. Safar ME. Systolic blood pressure, pulse pressure and arterial stiffness as 356 cardiovascular risk factors. Curr Opin Nephrol Hypertens 2001;10:257-61.
- 357
  3. Chirinos JA, Zambrano JP, Chakko S et al. Relation between ascending aortic
  358 pressures and outcomes in patients with angiographically demonstrated coronary
  359 artery disease. Am J Cardiol 2005;96:645-8.
- 360 4. Domanski MJ, Sutton-Tyrrell K, Mitchell GF et al. Determinants and prognostic
  361 information provided by pulse pressure in patients with coronary artery disease
  362 undergoing revascularization. The Balloon Angioplasty Revascularization
  363 Investigation (BARI). Am J Cardiol 2001;87:675-9.
- 364 5. Warren J, Nanayakkara S, Andrianopoulos N et al. Impact of Pre-Procedural Blood
  365 Pressure on Long-Term Outcomes Following Percutaneous Coronary Intervention. J
  366 Am Coll Cardiol 2019;73:2846-2855.
- 367 6. Vranckx P, Valgimigli M, Juni P et al. Ticagrelor plus aspirin for 1 month, followed
  368 by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for
  369 12 months, followed by aspirin monotherapy for 12 months after implantation of a
  370 drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet
  371 2018;392:940-949.
- 372 7. Serruys PW, Tomaniak M, Chichareon P et al. Patient-oriented composite endpoints
  373 and net adverse clinical events with ticagrelor monotherapy following percutaneous
  374 coronary intervention: Insights from the randomized GLOBAL LEADERS trial.
  375 EuroIntervention 2019.
- Vranckx P, Valgimigli M, Windecker S et al. Long-term ticagrelor monotherapy
   versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients
   undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL
   LEADERS trial. EuroIntervention 2016;12:1239-1245.
- Mehran R, Rao SV, Bhatt DL et al. Standardized bleeding definitions for
  cardiovascular clinical trials: a consensus report from the Bleeding Academic
  Research Consortium. Circulation 2011;123:2736-47.
- 383 10. Garcia-Garcia HM, McFadden EP, Farb A et al. Standardized End Point Definitions
  384 for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus
  385 Document. Circulation 2018;137:2635-2650.
- Franklin SS, Gustin Wt, Wong ND et al. Hemodynamic patterns of age-related
  changes in blood pressure. The Framingham Heart Study. Circulation 1997;96:30815.
- Blacher J, Staessen JA, Girerd X et al. Pulse pressure not mean pressure determines
  cardiovascular risk in older hypertensive patients. Arch Intern Med 2000;160:1085-9.
- 391 13. Domanski M, Norman J, Wolz M, Mitchell G, Pfeffer M. Cardiovascular risk
  392 assessment using pulse pressure in the first national health and nutrition examination
  393 survey (NHANES I). Hypertension 2001;38:793-7.
- Mitchell GF. Pulse pressure, arterial compliance and cardiovascular morbidity and mortality. Curr Opin Nephrol Hypertens 1999;8:335-42.
- Jankowski P, Kawecka-Jaszcz K, Czarnecka D. Ascending aortic blood pressure
  waveform is related to coronary atherosclerosis in hypertensive as well as in
  normotensive subjects. Blood Press 2007;16:246-53.

399	16.	Nakayama Y, Tsumura K, Yamashita N, Yoshimaru K, Hayashi T. Pulsatility of
400		ascending aortic pressure waveform is a powerful predictor of restenosis after
401		percutaneous transluminal coronary angioplasty. Circulation 2000;101:470-2.
402	17.	Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating
403		ascending aortic pressure from the radial artery pressure waveform. Hypertension
404		2001;38:932-7.
405	18.	Weber T, Auer J, O'Rourke MF et al. Arterial stiffness, wave reflections, and the risk
406		of coronary artery disease. Circulation 2004;109:184-9.
407	19.	Weber T, Auer J, O'Rourke M F et al. Increased arterial wave reflections predict
408		severe cardiovascular events in patients undergoing percutaneous coronary
409		interventions. Eur Heart J 2005;26:2657-63.
410	20.	Safar ME, Blacher J, Jankowski P. Arterial stiffness, pulse pressure, and
411		cardiovascular disease-is it possible to break the vicious circle? Atherosclerosis
412		2011;218:263-71.
413	21.	Jankowski P, Bilo G, Kawecka-Jaszcz K. The pulsatile component of blood pressure:
414		its role in the pathogenesis of atherosclerosis. Blood Press 2007;16:238-45.
415	22.	Van Herck JL, De Meyer GR, Martinet W et al. Impaired fibrillin-1 function
416		promotes features of plaque instability in apolipoprotein E-deficient mice. Circulation
417		2009;120:2478-87.
418	23.	Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P. Circumferential stress and matrix
419		metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque
420		rupture. Arterioscler Thromb Vasc Biol 1996;16:1070-3.
421	24.	Shiratsuch H, Basson MD. Differential regulation of monocyte/macrophage cytokine
422		production by pressure. Am J Surg 2005;190:757-62.
423	25.	Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in
424		predicting risk for coronary heart Disease? The Framingham heart study. Circulation
425		1999;100:354-60.
426	26.	Leung MC, Meredith IT, Cameron JD. Aortic stiffness affects the coronary blood
427		flow response to percutaneous coronary intervention. Am J Physiol Heart Circ
428		Physiol 2006;290:H624-30.
429	27.	Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with
430		acute coronary syndromes. N Engl J Med 2009;361:1045-57.
431	28.	Campo G, Vieceli Dalla Sega F, Pavasini R et al. Biological effects of ticagrelor over
432		clopidogrel in patients with stable coronary artery disease and chronic obstructive
433		pulmonary disease. Thromb Haemost 2017;117:1208-1216.
434	29.	Alemayehu M, Kim RB, Lavi R et al. Effect of Ticagrelor Versus Clopidogrel on
435		Vascular Reactivity. J Am Coll Cardiol 2017;69:2246-2248.
436	30.	Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ.
437		Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically
438		relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol
439		Ther 2014;19:209-19.
440	31.	Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor:
441		evidence and potential clinical relevance. J Am Coll Cardiol 2014;63:2503-2509.
442	32.	Hasko G, Pacher P. Regulation of macrophage function by adenosine. Arterioscler
443		Thromb Vasc Biol 2012;32:865-9.
444	33.	Jeong HS, Hong SJ, Cho SA et al. Comparison of Ticagrelor Versus Prasugrel for
445		Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in
446		Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome
447		Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial. JACC
448		Cardiovasc Interv 2017;10:1646-1658.

- 449 34. Bonello L, Frere C, Cointe S et al. Ticagrelor increases endothelial progenitor cell
  450 level compared to clopidogrel in acute coronary syndromes: A prospective
  451 randomized study. Int J Cardiol 2015;187:502-7.
- 452 35. Vlachopoulos C, Dima I, Aznaouridis K et al. Acute systemic inflammation increases
  453 arterial stiffness and decreases wave reflections in healthy individuals. Circulation
  454 2005;112:2193-200.
- 455 36. Kai H, Kohro T, Fukuda K, Yamazaki T, Nagai R. Impact of systolic blood pressure
  456 on hemorrhagic stroke in patients with coronary artery disease during anti-platelet
  457 therapy: The Japanese Coronary Artery Disease (JCAD) study. Int J Cardiol
  458 2016;224:112-113.
- 459 37. Arima H, Anderson C, Omae T et al. Effects of blood pressure lowering on
  460 intracranial and extracranial bleeding in patients on antithrombotic therapy: the
  461 PROGRESS trial. Stroke 2012;43:1675-7.
- 462 38. Toyoda K, Yasaka M, Uchiyama S et al. Blood pressure levels and bleeding events
  463 during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT)
  464 Study. Stroke 2010;41:1440-4.
- 465 39. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the
  466 management of arterial hypertension. Eur Heart J 2018;39:3021-3104.
- 467 40. Lip GY, Felmeden DC, Dwivedi G. Antiplatelet agents and anticoagulants for
  468 hypertension. Cochrane Database Syst Rev 2011:CD003186.
- 469 41. Roman MJ, Devereux RB, Kizer JR et al. Central pressure more strongly relates to
  470 vascular disease and outcome than does brachial pressure: the Strong Heart Study.
  471 Hypertension 2007;50:197-203.
- 472 42. Jankowski P, Kawecka-Jaszcz K, Czarnecka D et al. Ascending aortic, but not
  473 brachial blood pressure-derived indices are related to coronary atherosclerosis.
  474 Atherosclerosis 2004;176:151-5.
- 475 43. Steppan J, Barodka V, Berkowitz DE, Nyhan D. Vascular stiffness and increased
  476 pulse pressure in the aging cardiovascular system. Cardiol Res Pract
  477 2011;263585.
- 478 44. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C.
  479 Prediction of cardiovascular events and all-cause mortality with central 480 haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010;31:1865-
- 481 71.
  482 45. Gurbel PA, Bliden KP, Butler K et al. Response to ticagrelor in clopidogrel
  483 nonresponders and responders and effect of switching therapies: the RESPOND
- 484 study. Circulation 2010;121:1188-99.
- 485 46. Floyd CN, Passacquale G, Ferro A. Comparative pharmacokinetics and
  486 pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their
  487 clinical implications. Clin Pharmacokinet 2012;51:429-42.
- 488

	PP < 60	<b>PP</b> ≥ 60	p-valu
	(n=7965)	(n=7971)	
Age, mean (SD)	62.08 (10.29)	66.99 (9.73)	< 0.00
BMI, mean (SD)	28.16 (4.54)	28.22 (4.65)	0.422
Diabetes mellitus	1736 (21.8)	2294 (28.8)	< 0.00
Insulin-dependent diabetes mellitus	481 (6.1)	740 (9.3)	< 0.00
Male	6427 (80.7)	5799 (72.8)	< 0.00
Hypertension	5375 (67.7)	6322 (79.5)	< 0.00
Hypercholesterolemia	5263 (68.3)	5490 (71.1)	< 0.00
Smoking history	2397 (30.1)	1765 (22.1)	< 0.00
Peripheral vascular disease	392 (5.0)	608 (7.7)	< 0.00
COPD	392 (4.9)	429 (5.4)	0.197
History of bleeding	50 (0.6)	48 (0.6)	0.921
Renal failure	895 (11.3)	1272 (16.0)	< 0.00
Previous stroke	197 (2.5)	224 (2.8)	0.200
Previous MI	1937 (24.4)	1764 (22.2)	0.001
Previous PCI	2565 (32.2)	2640 (33.2)	0.219
Previous CABG	405 (5.1)	533 (6.7)	< 0.00
Clinical presentation			
Stable CAD	3866 (48.5)	4592 (57.6)	< 0.00
Unstable angina	1026 (12.9)	994 (12.5)	0.450
NSTEMI	1818 (22.8)	1549 (19.4)	< 0.00
STEMI	1255 (15.8)	836 (10.5)	< 0.00

# **Table 1: Baseline clinical characteristics according to pulse pressure groups**

- 490 Data shown are n (%), unless otherwise indicated. SD: standard deviation; BMI: body mass
- 491 index; COPD: chronic obstructive pulmonary disease; MI: myocardial infarction; PCI:
- 492 percutaneous coronary intervention; CABG: coronary artery bypass grafting; CAD: coronary
- 493 artery disease; NSTEMI: non-ST-elevation myocardial infarction; STEMI: ST-elevation
- 494 myocardial infarction.

Outcomes	<b>PP</b> < 60	<b>PP</b> ≥ 60	Unadjusted HR	р-	Adjusted HR*	p-value	
at 2 years	(n=7965)	(n=7971)	(95% CI)	value	(95% CI)		
Death/Q-wave MI	309 (3.9)	342 (4.3)	1.11 (0.95-1.29)	0.190	0.86 (0.73-1.01)	0.058	
POCE	1001 (12.7)	1172 (14.9)	1.19 (1.09-1.29)	< 0.001	1.09 (1.00-1.19)	0.051	
BARC 3 or 5	136 (1.7)	195 (2.5)	1.44 (1.16-1.79)	0.001	1.11 (0.89-1.40)	0.355	
NACE	1083 (13.7)	1290 (16.4)	1.21 (1.12-1.31)	< 0.001	1.09 (1.01-1.19)	0.037	

495 Table 2: Clinical and safety outcomes at 2 years according to pulse pressure groups

496 Data shown are number of events (Kaplan-Meier estimates).

497 \* Adjusted for age, diabetes, sex, hypertension, peripheral vascular disease, renal failure, history of myocardial infarction, history of coronary

498 artery bypass grafting and presentation of acute coronary syndrome. Death/Q-wave MI: composite of all-cause mortality or non-fatal, new Q-wave

499 myocardial infarction; POCE: patient oriented composite endpoints; BARC: bleeding academic research consortium; NACE: net adverse clinical

500 events.

	PP<60				<b>PP</b> ≥ 60				
Outcomes	Reference	Experimental	Adjusted HR*†	p-value†	Reference	Experimental	Adjusted HR*:	p-value‡	p-value
at 2 years	(n=3928)	(n=4037)	(95% CI)		(n=4043)	(n=3928)	(95% CI)		for interaction
Death /									
Q-wave MI	173 (4.4)	136 (3.4)	0.77 (0.61-0.96)	0.022	175 (4.3)	167 (4.3)	0.98 (0.79-1.22)	0.873	0.103
POCE	528 (13.5)	473 (11.9)	0.86 (0.76-0.98)	0.019	600 (14.9)	572 (14.8)	0.99 (0.88-1.11)	0.905	0.132
BARC 3 or 5	80 (2.1)	56 (1.4)	0.69 (0.49-0.97)	0.036	89 (2.2)	106 (2.6)	1.28 (0.96-1.71)	0.085	0.008
NACE	574 (14.7)	509 (12.8)	0.85 (0.76-0.96)	0.009	660 (16.5)	630 (16.3)	0.99 (0.89-1.12)	0.975	0.081
502 Data	shown are nu	mber of events (K	aplan-Meier estima	ites).					


## 501 **Table 3: Clinical and safety outcomes at 2 years according to antiplatelets therapies in pulse pressure groups**

503 \* Adjusted for age, diabetes, sex, hypertension, peripheral vascular disease, renal failure, history of myocardial infarction, history of coronary


- 504 artery bypass grafting and presentation of acute coronary syndrome.
- 505 † Values calculated from the experimental versus reference antiplatelet therapy within subjects with pule pressure < 60.
- 506  $\ddagger$  Values calculated from experimental versus reference antiplatelet therapy within subjects with pule pressure  $\ge 60$ .
- 507 PP: pulse pressure; Death/Q-wave MI: composite of all-cause mortality or non-fatal, new Q-wave myocardial infarction; POCE: patient oriented
- 508 composite endpoints; BARC: bleeding academic research consortium; NACE: net adverse clinical events

Version 09 – July 3<sup>rd</sup> 2019


- 509 Figure 1. Spline representation of the unadjusted hazard ratios for patient oriented composite endpoints (POCE) and major bleeding (BARC 3 or
- 510 5) at 2 years according to pulse pressure values.




- 513 Figure 2A: Interaction of the two antiplatelet therapies on the clinical endpoint POCE in the
- 514 pulse pressure groups.



- 516 **Figure 2B**: Interaction of the two antiplatelet therapies on the safety endpoint BARC type 3 or
- 517 5 in the pulse pressure groups.



- 519 Figure 2C: Interaction of the two antiplatelet therapies on the combination of clinically
- 520 relevant and safety-related bleeding events NACE in the pulse pressure groups.



521